Prices & Benefits

Benefits

Reimbursement of 75% of the Purchase Price - Money Back Guarantee Inhaler Trial Program

We at Syqe believe it is our responsibility to relieve the suffering of as many patients as possible using our technology. We have complete confidence in our inhaler, which is research-based in reducing pain intensity and improving the quality of life and daily function. Therefore, we decided to offer patients with a suitable license to purchase the SyqeAir Inhaler for a trial period, with the option to return it and receive a refund of 75% of the purchase price.

  • Participation is subject to the program conditions and the completion of the enrollment process
  • The refund will be 75% of the price paid and will be given subject to program conditions, only after taking part in Syqe Medical’s Patient Support Program for at least 45 subsequent days and no longer than 90 days since the day of purchase of the inhaler
  • Enrolling in the program is relevant for Inhalers purchased by 31.12.2022
  • Purchasing the cartridges for SyqeAir Inhaler is subject to having a valid license for the purchase and possession of dangerous drugs and valid delivery certificates
  • A valid license for SyqeAir cartridges must be presented when purchasing the inhaler
  • In adherence to the medical indications approved by the Israeli Ministry of Health. Use of the Inhaler is conditional on the recommendation of a physician and a license according to Protocol 106. This does not constitute a medical recommendation in any way.
300 NIS Discount on the Purchase of the Inhaler in Super-Pharm Chain

The cooperation with Super-Pharm allows higher availability of SyqeAir Inhalers across the country – the discount will make the purchase more affordable. This is in accordance with our vision of making our advanced technology accessible to as many people as possible in the fastest possible way.

A discount coupon of NIS 300 will be sent to you by Syqe's Customer Experience team, and you can use it in selected Super-Pharm branches until 31.12.2022. The coupon is personal and non-transferable. A valid cartridge license must be presented when purchasing the inhaler.

Full Reimbursement for the Disabled Patients of the Ministry of Defense - And the Military and Security Forces Personnel Recognized for the Treatment

We are proud to take part in reducing the pain and suffering of the people who risked their lives for the safety of our country.

Starting June 2021, medical cannabis treatment utilizing the SyqeAir Inhaler is fully funded to all disabled military and security forces veterans, given that the treatment was approved due to known disability and recommended by a professional physician.

To verify eligibility for participation in the program, contact our service center at *2064.

To purchase the SyqeAir Inhaler and cartridges, one must have a license for medical cannabis that clearly states the following method of use: cannabis for the administration of cartridges for inhaler type Sativa T20/C4. For receiving eligibility and issuing a suitable medical cannabis license, see a specialist.

Purchasing the Inhaler is possible in one of the licensed pharmacies for medical cannabis sale.

List of pharmacies.

Upon purchase, one must present the license and prescriptions.

After purchasing the Inhaler and before starting the treatment, please call our service center at *2064, and schedule an initial training with a registered nurse. The training, personal support, and direct response to all of your questions are given as part of Syqe’s service.

Full Subsidy for Work Injury Victims - Recognized by Social Security

Subsidy of medical cannabis treatment for work injury victims:

According to the Social Security law, work injury victims of all HMOs (Kupot Cholim) are entitled to a refund for medical cannabis treatment-related expenses. The refund is given upon presenting original invoices/receipts for every purchase and formal approval for being a work injury victim.

Full Reimbursement for Victims of Hostilities - Recognized by Social Security

Funding for medical cannabis and the SyqeAir Inhaler for victims of hostilities:

Victims of hostilities who have been recognized and licensed to use medical cannabis due to their disability are eligible for funding of their expenses on cannabis and related equipment. To exercise this right, contact the attending Social Security office and present a valid license from the Ministry of Health and prescriptions indicating the type of cannabis and monthly dose.

50% Discount on the Purchase of the Inhaler - For Endometriosis Patients Under Meuhedet's Supplementary Insurances

For the first time in Israel and only in the supplementary insurances of Meuhedet - "Adif" and "Si": Endometriosis patients with suitable licenses are entitled to a 50% discount on the purchase of the SyqeAir Inhaler for a metered and consistent treatment using medical cannabis for the reduction of the intensity of the pain caused by the disease.

The price of the inhaler after discount: 975 NIS (instead of 1,950 NIS)

The price of a cartridge after discount: 666 NIS (instead of 740 NIS)

The sum value of the discounts in the first year of treatment: 1,863 NIS (for purchase of one cartridge per month).

Entitled to the discounts are licensees for inflorescences types T20C4 | T15C3 | T10C2 and/or licensees for a cartridge for inhaler type Sativa T20C4. To receive the discounts, please contact Meuhedet's cannabis center via email: m.c@meuhedet.co.il.

To receive an explanation of the benefits and operation of the inhaler and to join our Patient Support Program to receive nursing training and guidance (free of charge for the first year of treatment) in which a personal treatment plan will be tailored for you according to your medical condition and your physician's recommendation, call us at *2064.

In accordance with the medical indications approved by the Israeli Ministry of Health. The use of the Inhaler is subject to the recommendation of a physician and a license for medical cannabis use according to the requirements of the law. This does not constitute a medical recommendation in any way.

1. Eisenberg, E, et al. (2014). J Pain Palliat Care Pharmacother, 28(3), 216-225.
2. Vulfsons, S. et al. (2020). Palliative & Supportive Care, 18(1), 12-17.‏
3. Almog S, et al. European Journal of Pain, 24(8), 1505-1516.
4. Aviram J, et al. (2022) PAIN Reports. 7(3). e1011.

Skip to content